| 何龙光,莫怡超,陈钦寿,阮梓康,高 毅.乙肝相关性肝癌组织BCLAF1、SETDB1表达与临床病理特征和术后预后的关系研究[J].现代生物医学进展英文版,2024,(8):1450-1454. |
| 乙肝相关性肝癌组织BCLAF1、SETDB1表达与临床病理特征和术后预后的关系研究 |
| Study on the Relationship between the Expression of BCLAF1 and SETDB1 in Hepatitis B-Related Hepatocellular Carcinoma and Clinicopathological Features and Prognosis after Operation |
| Received:November 23, 2023 Revised:December 18, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.08.008 |
| 中文关键词: 乙肝相关性肝癌 BCLAF1 SETDB1 临床病理特征 预后 |
| 英文关键词: Hepatitis B-related hepatocellular carcinoma BCLAF1 SETDB1 Clinicopathological features Prognosis |
| 基金项目:广东省医学科学技术研究基金项目（B2021156） |
|
| Hits: 300 |
| Download times: 193 |
| 中文摘要: |
| 摘要 目的：探讨乙肝相关性肝癌组织Bcl-2相关转录因子-1（BCLAF1）、组蛋白甲基化酶SET结构域分支型1（SETDB1）表达与临床病理特征和术后预后的关系。方法：选择2018年1至2020年6月南方医科大学珠江医院和高州市人民医院收治的127例行根治性手术切除的乙肝相关性肝癌患者，取手术切除的癌组织和旁组织，采用免疫组化法检测BCLAF1、SETDB1表达，分析BCLAF1、SETDB1表达与临床病理特征的关系。术后随访3年，Kaplan-Meier生存曲线分析BCLAF1、SETDB1不同表达患者生存差异，多因素Cox回归分析影响乙肝相关性肝癌患者预后的因素。结果：癌组织BCLAF1、SETDB1阳性表达率高于癌旁组织（P＜0.05）。低分化、TNM分期IIIa期、门脉侵犯、淋巴结转移患者癌组织中BCLAF1、SETDB1阳性表达率高于中高分化、TNM分期I～II期、无门脉侵犯、无淋巴结转移患者癌组织（P＜0.05）。BCLAF1阳性表达、SETDB1阳性表达乙肝相关肝癌患者3年总生存（OS）率低于BCLAF1阴性表达、SETDB1阴性表达乙肝相关肝癌患者（P＜0.05）。多因素Cox回归分析显示淋巴结转移、BCLAF1阳性表达、SETDB1阳性表达是乙肝相关肝癌患者预后不良的危险因素（P＜0.05）。结论：乙肝相关肝癌组织中BCLAF1、SETDB1阳性表达率增高，BCLAF1、SETDB1阳性表达与低分化、TNM分期、门脉侵犯、淋巴结转移和预后不良有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between the expression of Bcl-2-related transcription factor-1 (BCLAF1) and histone methylase SET domain branch type 1 (SETDB1) in hepatitis B-related hepatocellular carcinoma and clinicopathological features and prognosis after operation. Methods: 127 patients with hepatitis B-related hepatocellular carcinoma underwent radical resection in Zhujiang Hospital of Southern Medical University and Gaozhou People's Hospital from January 2018 to June 2020 were selected, the resected cancer tissues and adjacent tissues were taken, and the expression of BCLAF1 and SETDB1 were detected by immunohistochemistry, the relationship between the expression of BCLAF1 and SETDB1 and clinicopathological features were analyzed. 3 years after follow up, the survival differences of patients with different expressions of BCLAF1 and SETDB1 were analyzed by Kaplan-Meier survival curve, the factors affecting the prognosis of patients with hepatitis B-related hepatocellular carcinoma were analyzed by multivariate Cox regression analysis. Results: The positive expression rates of BCLAF1 and SETDB1 in cancer tissues were higher than those in adjacent tissues (P<0.05). The positive expression rates of BCLAF1 and SETDB1 in cancer tissues of patients with poor differentiation, TNM stage IIIa, portal vein invasion and lymph node metastasis were higher than those in cancer tissues of patients with moderate to high differentiation, TNM stage I~II, no portal vein invasion and no lymph node metastasis (P<0.05). The 3-year overall survival (OS) rate in HBV-related HCC patients with BCLAF1 positive expression and SETDB1 positive expression were lower than those in HBV-related HCC patients with BCLAF1 negative expression and SETDB1 negative expression (P<0.05). Multivariate Cox regression analysis showed that lymph node metastasis, BCLAF1 positive expression and SETDB1 positive expression were risk factors for poor prognosis in patients with hepatitis B-related hepatocellular carcinoma (P<0.05). Conclusion: The positive expression rates of BCLAF1 and SETDB1 in hepatitis B-related hepatocellular carcinoma tissues are increase, the positive expression of BCLAF1 and SETDB1 are relate to poor differentiation, TNM stage, portal vein invasion, lymph node metastasis and poor prognosis. |
|
View Full Text
View/Add Comment Download reader |
| Close |
